Reneo Financial Statements From 2010 to 2024

RPHMDelisted Stock  USD 18.20  1.40  8.33%   
Reneo Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Reneo Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Reneo Pharmaceuticals financial statements helps investors assess Reneo Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Reneo Pharmaceuticals' valuation are summarized below:
Reneo Pharmaceuticals does not presently have any trending fundamental ratios for analysis.
Check Reneo Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Reneo Pharmaceuticals' main balance sheet or income statement drivers, such as , as well as many indicators such as . Reneo financial statements analysis is a perfect complement when working with Reneo Pharmaceuticals Valuation or Volatility modules.
  
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

Reneo Pharmaceuticals Company Return On Equity Analysis

Reneo Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

 = 

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Reneo Pharmaceuticals Return On Equity

    
  -0.54  
Most of Reneo Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Reneo Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition

Based on the latest financial disclosure, Reneo Pharmaceuticals has a Return On Equity of -0.54. This is 97.75% lower than that of the Biotechnology sector and 98.52% lower than that of the Health Care industry. The return on equity for all United States stocks is 74.19% higher than that of the company.

Reneo Pharmaceuticals Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Reneo Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Reneo Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Reneo Pharmaceuticals competition to find correlations between indicators driving Reneo Pharmaceuticals's intrinsic value. More Info.
Reneo Pharmaceuticals is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Reneo Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

About Reneo Pharmaceuticals Financial Statements

Reneo Pharmaceuticals investors utilize fundamental indicators, such as revenue or net income, to predict how Reneo Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company was incorporated in 2014 and is headquartered in Irvine, California. Reneo Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 29 people.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Other Consideration for investing in Reneo Stock

If you are still planning to invest in Reneo Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reneo Pharmaceuticals' history and understand the potential risks before investing.
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk